ArticleFrontiers in endocrinology2025
U-TXM: a novel biomarker for early detection of diabetic kidney disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease. This study aimed to investigate the potential of urinary 11-dehydrothromboxane B2 (U-TXM) as a biomarker for the early detection of DKD. Materials and methods: A total of 690 patients were enrolled, including 422 with diabetes mellitus (DM) and 268 with DKD. Patients with type 1, type 2, and other specific forms of diabetes were consecutively recruited from the Department of Endocrinology, Yijishan Hospital of Wannan Medical College (April-September 2024). U-TXM levels were measured and their clinical relevance to DKD was evaluated using correlation analysis, logistic regression, and receiver operating characteristic (ROC) curve analysis. Results: Urinary U-TXM levels were significantly higher in patients with DKD than in those with DM (median: 1158.05 vs. 960.44 pg/mg Cr; Conclusion: U-TXM shows potential as a biomarker for DKD, particularly in patients at early disease stages. Validation through longitudinal, multicenter, and comparative studies is required to confirm its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.